NCT06341647View on ClinicalTrials.gov

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

February 28, 2029

Conditions
Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

AB-201

NK Cell Therapy

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY